Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of British Columbia
$27,000.00
Evaluating longitudinal health-related quality of life measures to facilitate implementation in clinical trials for primary ciliary dyskinesia
EF 2025-26
Résumé
Primary Ciliary Dyskinesia (PCD) is a genetic disease that damages motile cilia, eventually leading to serious lung disease. These hairlike structures help clear mucus from the airways, which prevents infection and lung damage. In addition, cilia are important for hearing and sinus health as well as reproduction. PCD measurably lowers quality of life (QOL), defined as a patient’s own opinion of their overall health and wellbeing. Chronic respiratory symptoms, lengthy treatments, poor sleep, and disease flare ups (known as pulmonary exacerbations) decrease QOL in people with PCD. Research studying new treatments must show improvements in QOL using the QOL-PCD questionnaire, as it is a core outcome of interest for regulators. Researchers have studied QOL over short periods, but long-term evaluations are limited.
My study will assess changes in overall QOL and its seven key domains using data collected from 150 people with PCD across North America, each followed for one year between 2022-2025. My goal is to compare how QOL scores change during pulmonary exacerbations along with other objective health measures such as lung function (e.g., does QOL decrease as lung function decreases). If QOL changes correlate with clinical measures, this will help implement QOL-PCD as a core clinical trial outcome measure. I will also more closely evaluate the QOL-PCD, such as identifying which influences are relevant in childhood, describing whether QOL changes when patients are stable, and exploring how much QOL scores must change to be considered clinically relevant. This study will help healthcare providers measure and manage QOL changes in people with PCD, while also supporting research to evaluate how new treatments in clinical trials impact QOL.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573027
Name
Tuff-Gordon Eliza M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating longitudinal health-related quality of life measures to facilitate implementation in clinical trials for primary ciliary dyskinesia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Chest Exacerbations; Children'S Health Research; Clinical Trials; Cohort Study; Health-Related Quality Of Life; Longitudinal Data Analysis; Patient-Related Outcome Measures; Primary Cillary Dyskinesia; Qol-Pcd; Rare Diseases
Abstract
Primary Ciliary Dyskinesia (PCD) is a genetic disease that damages motile cilia, eventually leading to serious lung disease. These hairlike structures help clear mucus from the airways, which prevents infection and lung damage. In addition, cilia are important for hearing and sinus health as well as reproduction. PCD measurably lowers quality of life (QOL), defined as a patient’s own opinion of their overall health and wellbeing. Chronic respiratory symptoms, lengthy treatments, poor sleep, and disease flare ups (known as pulmonary exacerbations) decrease QOL in people with PCD. Research studying new treatments must show improvements in QOL using the QOL-PCD questionnaire, as it is a core outcome of interest for regulators. Researchers have studied QOL over short periods, but long-term evaluations are limited.
My study will assess changes in overall QOL and its seven key domains using data collected from 150 people with PCD across North America, each followed for one year between 2022-2025. My goal is to compare how QOL scores change during pulmonary exacerbations along with other objective health measures such as lung function (e.g., does QOL decrease as lung function decreases). If QOL changes correlate with clinical measures, this will help implement QOL-PCD as a core clinical trial outcome measure. I will also more closely evaluate the QOL-PCD, such as identifying which influences are relevant in childhood, describing whether QOL changes when patients are stable, and exploring how much QOL scores must change to be considered clinically relevant. This study will help healthcare providers measure and manage QOL changes in people with PCD, while also supporting research to evaluate how new treatments in clinical trials impact QOL.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tuff-Gordon, Eliza M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~